IMMIX BIOPHARMA DL-,0001 Aktie

Immix Biopharma presented strong clinical data on NXC-201 at the Morgan Stanley conference — a single-dose, BCMA-directed CAR-T therapy for AL amyloidosis — and highlighted a short median cytokine release syndrome duration of one day. The registration-relevant Phase II study NEXICART-2 includes 45 patients; top-line data are expected at the end of September 2024, followed by a planned BLA submission in March 2025. Management says the company has cash runway into mid-2028, will start a Phase III first-line comparison against the four-drug regimen with DARZALEX, sees competition from AbbVie and Regeneron, but remains confident in advantages in efficacy and tolerability. » Więcej na de.investing.com

Immix Biopharma shares fell about 11.6% intraday after it emerged that the CMO hired in March as “Dr. Richard Graydon” is in fact Ronald Fischer, a fugitive who was recently arrested. The incident raised questions about the company’s leadership due diligence and corporate governance, especially as Immix approaches the topline readout of the approval‑relevant NEXICART‑2 study. Elevated short interest of roughly 20% amplified selling volume and sped the decline. The company reported the immediate removal of the CMO in an 8‑K filing. » Więcej na de.investing.com

Immix Biopharma reports a 95% clinical response rate for its CAR‑T therapy NXC‑201 in AL amyloidosis. A $150 million capital raise in May 2026 secures funding for the research‑intensive company well into 2027. With the proceeds, Immix can independently advance the next steps toward market approval. » Więcej na finanzen.net